We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-10 of 11

FDA requires increased disclosure of bioequivalence studies for ANDA applicants
  • Gowling WLG
  • USA
  • February 9 2009

Effective July 15, 2009, the U.S. Food and Drug Administration (FDA) will require applicants of an abbreviated new drug application (ANDA) to submit all data from bioequivalence studies that have been conducted on the particular drug formulation submitted for approval.


Isabel Raasch
  • Gowling WLG


Scott E. Foster
  • Gowling WLG


James D. Baker
  • Gowling WLG


Denis Kolesnikov
  • Gowling WLG


Gordon Harris
  • Gowling WLG